Novavax Inc. ($NVAX) Stock Forecast: Down 5.2% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company specializing in developing and commercializing vaccines for infectious diseases, utilizing a recombinant protein approach and its patented Matrix-M adjuvant. The stock had a strong bearish movement today amidst recent market developments and investor sentiments.

Why is Novavax Inc. going down?

NVAX stock is down 5.2% on Apr 10, 2026 19:25

• Novavax's stock had a bearish movement despite outperforming competitors and the broader market in the past few days, indicating a shift in investor sentiment.
• The increase in price target to $18 from $16 and maintaining a Buy rating did not seem to positively impact the stock, suggesting other factors are at play.
• Criticisms regarding Novavax's strategy, calls to slash costs, and overhaul the board of directors might have contributed to the bearish movement as investors react to uncertainties surrounding the company's future direction.
• The lackluster Q4 earnings, projected revenue decline, and cash flow concerns highlighted in the analysis post-earnings could have further fueled the negative market sentiment towards Novavax, leading to the bearish movement.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc. (NVAX) stock rose 1.43% to $8.54 on Thursday, extending its gaining streak to four consecutive days. This performance outpaced the broader market, with the NASDAQ Composite Index and Dow Jones Industrial Average also seeing gains. The company's stock rallied on a strong trading day for the overall market.

https://www.marketwatch.com/data-news/novavax-inc-stock-outperforms-competitors-on-strong-trading-day-6f1b2ecc-ab54b0fa2bd3?mod=mw_quote_news

B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating

B. Riley has increased its price target for Novavax (NVAX) to $18 from $16, while maintaining a Buy rating on the stock. This adjustment reflects an updated outlook from the analyst firm regarding the biotechnology company. Novavax specializes in developing and commercializing vaccines for infectious diseases, utilizing a recombinant protein approach and its patented Matrix-M adjuvant.

https://www.marketscreener.com/news/b-riley-raises-price-target-on-novavax-to-18-from-16-keeps-buy-rating-ce7e50dbd089f722

Novavax (NVAX): Buy, Sell, or Hold Post Q4 Earnings?

This article analyzes Novavax (NVAX) following its Q4 earnings, expressing a lack of confidence in the stock. The analysis highlights three main concerns: lackluster revenue growth, projected significant revenue decline by Wall Street analysts, and a dropping free cash flow margin indicating the company is burning cash. Based on these factors, the article concludes that Novavax does not present an exciting investment opportunity.

https://www.tradingview.com/news/stockstory:0a494d4b8094b:0-novavax-nvax-buy-sell-or-hold-post-q4-earnings/

Shah Capital Blasts Novavax Strategy In New Letter To Board

Shah Capital has criticized Novavax's strategy in a new letter sent to the company's board. The article by Alaric DeArment highlights this development concerning the pharmaceutical company.

https://insights.citeline.com/scrip/scrip/business/strategy/shah-capital-blasts-novavax-strategy-in-new-letter-to-board-A6DIVMGGQFDHVFBDLLQJWCPK5Y/

Investor calls for Novavax to slash costs, cut board as vaccine sales disappoint

Activist investor Shah Capital is once again calling for significant changes at Novavax, urging the Gaithersburg-based company to slash costs and overhaul its board of directors. This marks the third time in two years that Shah Capital has pushed for a major shake-up, following disappointing vaccine sales. Novavax has already been reducing its footprint in Gaithersburg in an effort to cut expenses.

https://www.bizjournals.com/washington/news/2026/04/08/novavax-shah-capital-management-pfizer-sanofi.html

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.1% Today

Check Point Software Technologies Ltd. ($CHKP) Stock Forecast: Down 5.2% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Down 5.9% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Down 5.3% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.2% Today

Natera, Inc. ($NTRA) Stock Forecast: Down 7.8% Today

ServiceNow Inc. ($NOW) Stock Forecast: Down 7.4% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Down 5.1% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 17.4% Today

Novavax Inc. Price History

02.03.2026 - NVAX Stock was down 5.0%

• An investment firm, Shah Capital Management, significantly increased its stake in Novavax during Q4, showing confidence in the company's future despite the recent stock decline. This move could indicate a long-term positive outlook on NVAX.
• The appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research & Development brings in a seasoned professional with extensive experience in drug and vaccine development. This change in leadership might signal a strategic shift or renewed focus on research and development efforts.
• The underperformance of Novavax's stock compared to its competitors, despite positive quarterly earnings and revenue growth, suggests that market sentiment or external factors may be influencing investor behavior. This disparity could be a result of broader industry trends or specific company challenges that need addressing.
• The departure of the previous R&D chief after a short tenure and the subsequent internal promotion highlight potential internal restructuring within Novavax. This organizational change could be impacting investor confidence and contributing to the stock's bearish movement.

18.02.2026 - NVAX Stock was down 5.1%

• Despite recent positive developments and analyst support, Novavax Inc. (NVAX) observed a significant 5.56% decrease in its stock price today.
• The increase in institutional investment by Farallon Capital Management LLC, acquiring a notable amount of shares, did not appear to enhance the stock's performance on the current day.
• The varied assessments from analysts, ranging from reaffirmed Buy ratings to optimistic price forecasts, might not have counteracted the broader market sentiment affecting Novavax's stock.
• It seems that notwithstanding the company's impressive earnings report and innovative platform, external market conditions or profit-taking activities could have played a role in today's downward trend for Novavax Inc.

01.03.2026 - NVAX Stock was up 5.0%

• An increase in stake from Shah Capital Management and Novavax's strong quarterly earnings surpassing analyst predictions likely influenced the stock's upward movement.
• The appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research & Development may have boosted investor confidence in the company's future innovation efforts.
• Despite trailing behind its competitors recently, positive updates on leadership changes and financial results appear to have overshadowed these concerns and propelled the stock price higher.

19.02.2026 - NVAX Stock was down 7.8%

• Novavax Inc.'s (NVAX) stock closed 5.92% lower at $10.01 today, showing a strong bearish movement.
• The underperformance of NVAX compared to its competitors and the broader market can be attributed to several factors:
• The company is projected to incur losses for the current quarter and fiscal year despite recent positive earnings surprises, impacting investor sentiment.
• Continuous days of losses, including today, may have led investors to take profits after benefiting from the stock's momentum previously.
• The increase in stake by institutional investors like Farallon Capital Management LLC in NVAX could indicate confidence in the company's long-term potential. However, the mixed analyst outlook and the stock closing below its 52-week high reflect ongoing market uncertainty.
• The bearish movement of NVAX today is a result of profit-taking, investor cautiousness due to projected losses, and the influence of broader market trends on the stock's performance.

20.02.2026 - NVAX Stock was up 5.5%

• Novavax (NVAX) stock saw a significant 5.56% surge to $10.64 today.
• This growth is linked to the company's recent earnings report surpassing expectations, with earnings of $0.11 EPS beating predictions of -$0.66 and a substantial 66.6% year-over-year revenue increase to $136.4 million.
• Although there have been days where the stock didn't perform as well as competitors and the overall market, positive investor sentiment regarding Novavax's earnings surprises and company interest contributed to today's rise.
• Investors are cautiously observing Novavax's high 5.93 debt-to-equity ratio and the average "Hold" rating from brokerages, signaling a wary outlook despite recent positive developments.

30.02.2026 - NVAX Stock was down 5.1%

• Dr. Robert Walker's appointment as the new Executive Vice President and Head of Research & Development at Novavax was received positively, demonstrating the company's commitment to advancing its R&D efforts.
• Despite strong financial results in Q4 2025, the market's bearish reaction may be linked to uncertainties regarding the leadership transition and potential impacts on future vaccine projects.
• Trade ideas and analyses for Novavax on TradingView revealed a mix of bullish and bearish sentiments, highlighting differing investor opinions on the stock's future performance.
• Some traders showed optimism based on technical indicators and fundamental catalysts such as licensing agreements, while others adopted a cautious stance due to stock volatility and the importance of effective risk management strategies.

24.02.2026 - NVAX Stock was down 5.1%

• Novavax's stock showed minimal growth but lagged behind the overall market performance, hinting at negative investor sentiment.
• Regulatory filings by the company disclosed significant occurrences such as payments for milestones, FDA nods, and financial operations, potentially impacting market perception.
• Challenges persist for Novavax, including consecutive days of losses and weaker performance relative to industry peers, raising investor apprehensions.
• With a neutral "Hold" rating from brokerage firms, surpassing earnings, and heightened institutional investor interest, the stock displays a mixed outlook, prompting cautious market behavior.

08.03.2026 - NVAX Stock was up 5.6%

• A major investor in Novavax, Shah Capital, has initiated efforts to revamp the company's board and leadership, citing concerns about previous missteps and lower-than-expected vaccine sales.
• Criticisms from this investor regarding Novavax's direction and management have prompted a shareholder movement, increasing pressure on the company to make changes.
• Shah Capital's decision to vote against board nominees and executive pay has hinted at potential management changes within Novavax, resulting in a rise in the stock's value.
• Investor enthusiasm for Shah Capital's proposals for strategic changes, cost reductions, and a possible company sale has led to a positive market response, indicating optimism for a revitalization in Novavax's performance and shareholder interests.

17.02.2026 - NVAX Stock was up 5.8%

• A substantial increase in stake by Farallon Capital Management LLC, which acquired 764,000 shares of NVAX, reflects a firm belief in the company's future potential, contributing to the stock's positive movement.
• Jefferies' reiterated support with a Buy rating and optimistic outlook on NVAX, highlighting the company's adjuvant platform and key partnerships, likely bolstered investor confidence and drove the stock's upward trajectory.
• Utilization of AI analysis to indicate positive sentiment and propose specific trading approaches for NVAX may have attracted a larger investor base, adding to the bullish momentum.
• Despite lagging behind competitors on Thursday, the overall positive sentiment surrounding NVAX, buoyed by institutional backing and analyst support, overshadowed the short-term decline and propelled the stock upwards.

12.02.2026 - NVAX Stock was down 5.1%

• The decline in NVAX stock today may be due to profit-taking by investors following a recent strong uptrend post the company's improved financial performance.
• Despite the positive developments such as moving to profits from losses in vaccine revenue and securing key partnerships, there could be investor concerns about the sustainability of these gains and potential obstacles in the vaccine market.
• Market uncertainties regarding NVAX's reliance on partner-driven milestones and royalties could be prompting some selling pressure on the stock.
• While NVAX's long-term strategy and partnerships show promise, short-term market sentiment and profit-taking actions may have influenced today's decline.

10.03.2026 - NVAX Stock was down 5.2%

• Novavax's stock had a bearish movement despite outperforming competitors and the broader market in the past few days, indicating a shift in investor sentiment.
• The increase in price target to $18 from $16 and maintaining a Buy rating did not seem to positively impact the stock, suggesting other factors are at play.
• Criticisms regarding Novavax's strategy, calls to slash costs, and overhaul the board of directors might have contributed to the bearish movement as investors react to uncertainties surrounding the company's future direction.
• The lackluster Q4 earnings, projected revenue decline, and cash flow concerns highlighted in the analysis post-earnings could have further fueled the negative market sentiment towards Novavax, leading to the bearish movement.

27.02.2026 - NVAX Stock was down 5.5%

• The bearish movement in NVAX stock can be attributed to:
• Overall market underperformance: NVAX's decline occurred during a negative trading session for major indexes like the NASDAQ Composite and Dow Jones Industrial Average.
• Renewed scrutiny and volatility in the biotech sector: Investor attention on Novavax's pipeline updates and financial health amidst post-COVID revenue declines may have added pressure on the stock.
• Technical analysis signals: Algorithmic analysis highlighting a mid-channel oscillation pattern and divergent sentiment across different time horizons might have influenced traders' decisions.
• Despite a brief gain on Monday breaking a losing streak, NVAX continues to struggle to outperform the broader market, indicating ongoing challenges and uncertainties surrounding the company's future prospects.